EPCT-05. A PHASE I TRIAL OF THE CDK 4/6 INHIBITOR PALBOCICLIB IN PEDIATRIC PATIENTS WITH PROGRESSIVE OR REFRACTORY CNS TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY

PBTC-042 was a phase I trial of palbociclib to determine the maximum tolerated dose (MTD) and describe toxicities in children. Palbociclib is an oral, selective cyclin dependent kinase 4/6 inhibitor. METHODS: A rolling-6 design was utilized. Eligible patients were children ≥4 and ≤21 years-old with...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Mater, David, Gururangan, Sridharan, Leary, Sarah, Becher, Oren, Phillips, Joanna, Huang, Jie, Campagne, Olivia, Poussaint, Tina, Goldman, Stewart, Baxter, Patricia, Dhall, Girish, Robinson, Giles, DeWire-Schottmiller, Mariko, Hwang, Eugene, Stewart, Clinton, Onar-Thomas, Arzu, Dunkel, Ira, Fouladi, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Early Phase Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715509/
http://dx.doi.org/10.1093/neuonc/noaa222.129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715509/
http://dx.doi.org/10.1093/neuonc/noaa222.129

Ejemplares similares